Tysabri Re-Launch Timing Will Depend On Outcome Of Risk Management Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec/Elan could be prepared to get the multiple sclerosis drug back on the market within weeks of re-approval.
You may also be interested in...
Tysabri Re-Launch Approved With MRI Requirement
FDA clears Biogen Idec’s multiple sclerosis therapy to return to market under a special distribution program.
FDA Re-Approves Tysabri, Recommends Second-Line Use
Biogen Idec expects to re-launch the multiple sclerosis therapy in July.
Tysabri Re-Launch Approved With MRI Requirement
FDA clears Biogen Idec’s multiple sclerosis therapy to return to market under a special distribution program.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: